CDH17 and colorectal carcinoma: Taking all the therapeutic data together, we demonstrate that E8-PE38 immunotoxin shows great potential for CRC treatment, and immunotoxins targeting CDH17 might be developed as a novel adjuvant agent combined with standard drugs to treat CDH17-positive CRC.